文献速递姑息放疗与转移瘤

免疫治疗期间接受姑息性放疗的前瞻性研究

Prospective Study of Patients Treated with Palliative Radiation Therapy While on Immunotherapy.
PubMed 文献 · Adv Radiat Oncol · 2025-02-18

这项前瞻性观察研究纳入39例在28天内接受免疫治疗并转诊行姑息性放疗的晚期癌症患者,共50程放疗。联合治疗未出现可归因于联合治疗的3级及以上毒性,中位生存期11个月,3个月时26例可评估影像中14例(54%)野内缓解。

要点

  • 联合治疗未出现可归因于联合治疗的3级及以上毒性。
  • 3个月时26例可评估患者中14例(54%)野内缓解,3例(12%)疾病稳定。
  • 照顾者辅助的患者报告结局(PRO)收集提高了PRO数据收集的依从性且可行。

核心结论

  • 姑息性放疗在接受免疫治疗的患者中似乎安全,联合治疗未见明显毒性增加,照射野外缓解并不优于单用免疫治疗的预期,照顾者辅助PRO可提高依从性且可行。

研究设计与样本

  • 前瞻性观察研究,2017年1月至2019年9月在本中心筛查接受或计划28天内开始免疫治疗并转诊行姑息性放疗的晚期癌症患者,共39例患者接受50程姑息性放疗。

主要发现

  • 最常见原发癌为非小细胞肺癌(38%),其次为黑色素瘤(36%)。
  • 最常见放疗剂量为20 Gy分5次(42%)。
  • 87%的患者(34/39)单用程序性细胞死亡蛋白1抑制剂。
  • 未出现可归因于联合治疗的3级及以上毒性,队列中位生存期为11个月。
  • 3个月时26例有影像可评估RECIST v1.1,14/26(54%)野内缓解,3/26(12%)疾病稳定(伴野外混合缓解)。

关键数值与推荐

  • 放疗剂量与分割由治疗放疗肿瘤科医生决定,免疫治疗按标准治疗流程给予。
  • 主要结局为3个月毒性,次要结局包括放疗后1、3、6个月CT按RECIST v1.1评估缓解。

临床怎么用

  • 对接受免疫治疗的患者行姑息性放疗时,可参考本研究的安全性观察,联合治疗未见明显毒性增加。
  • 可采用照顾者辅助PRO收集以提高PRO数据依从性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To prospectively document the outcomes of patients treated with palliative radiation therapy (RT) who are receiving immunotherapy. METHODS AND MATERIALS: Patients with advanced cancer receiving or planning to commence immunotherapy within 28 days who were referred for palliative RT at our center between January 2017 and September 2019 were screened for participation in this prospective observational study. Demographic and treatment data, along with patient-reported outcomes (PROs) using the Edmonton Symptom Assessment Scale for cancer, were collected at baseline, after 1 month, and then every 3 months for up to 1 year or until death. RT dose and fractionation were at the discretion of the treating radiation oncologist. Immunotherapy was given as per the standard of care protocol. The primary outcome was 3-month toxicity. Secondary outcomes included response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) response on computed tomography scan performed 1, 3, and 6 months post-RT. The feasibility of enhancing PRO compliance using caregiver-aided PROs and virtual PRO collection was explored. RESULTS: Thirty-nine patients who received 50 courses of palliative RT (most often for pain) and who also received immunotherapy within 28 days of RT were evaluated for toxicity at 3 months post-RT. The most common primary cancer was non-small cell lung cancer (38%), followed by melanoma (36%). The most common RT dose was 20 Gy in 5 fractions (42%). 87% of patients (34/39) received a programmed cell death protein 1 inhibitor alone. An interval of <14 days between RT and immunotherapy. No grade 3 or higher toxicity was attributable to combined treatment. The median survival for the cohort was 11 months. At 3 months, 26 patients had imaging available for RECIST v1.1; 14 of 26 (54%) had an in-field response, and 3 of 26 (12%) had stable disease (with mixed out-of-field response). Compliance with PROs was 79% (31/39) at 1 month and 69% (27/39) at 3 months. Ten of the 31 patients (32%) and 11 of 31 patients (41%) used caregiver-aided PRO collection. CONCLUSIONS: Palliative RT appears safe in patients receiving immunotherapy with no apparent increase in toxicity because of the combination. Responses out of irradiated volumes were no better than expected than with immunotherapy alone. Caregiver-aided PROs improved compliance with PRO data collection and were feasible.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Harris G, Bang A, Wong RKS, et al. Prospective Study of Patients Treated with Palliative Radiation Therapy While on Immunotherapy. Adv Radiat Oncol. 2025. PMID: 40213311. doi:10.1016/j.adro.2025.101741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。